Our free daily oncology focused e-news service.
(AbbVie) June 15, 2018 - AbbVie, a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURANO trial of venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).
read corporate press release(Novartis) June 15, 2018 – Novartis announced today results from a new comparison study showing that Jakavi® (ruxolitinib)-treated patients with polycythemia vera (PV), who were resistant or intolerant to hydroxyurea (HU), had a significantly reduced risk of thrombosis (blood clots) and death compared to PV patients who received best available therapy.
read corporate press release(Novartis) June 15, 2018 – Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).
read corporate press release(NASDAQ) June 15, 2018 - Consistently high responses in patients with an EZH2 activating mutation; durable clinical responses and progression-free survival observed in patients with or without an EZH2 activating mutation.
read article(DigitalJournal.com) June 15, 2018 - MorphoSys AG today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. The trial evaluates MorphoSys's proprietary hemato-oncological drug candidate MOR208 in combination with the cancer drug idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), who progressed on or were intolerant to ibrutinib therapy.
read article(BMS) June 15, 2018 - This is China’s first and only PD-1 inhibitor and is the only Immuno-Oncology (I-O) agent to demonstrate a survival benefit compared with chemotherapy, based on data from the pivotal Phase 3 CheckMate -078 trial, in which 90% of the patients enrolled were Chinese.
read corporate press release(PharmaTimes [UK]) June 15, 2018 - The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.
read article(Forbes) June 15, 2018 - Bluebird Bio's experimental gene therapy LentiGlobin is helping some patients two life-threatening forms of inherited anemia avoid blood transfusions.
read article(STAT Plus) June 14, 2018 - With little fanfare and minimal debate, a key Senate committee voted Thursday to advance legislation that aims to spur the development of new generic drugs and in turn, lower drug prices.
read article (paid subscription required)
